Bleomycin-Induced Dermal Fibrosis (Osmotic Pump)

Description

The systemic (SC osmotic pump) bleomycin-induced Dermal fibrosis model is induced by subcutaneously (SC) administering bleomycin over the course of 28 days. To induce disease, an osmotic pump containing bleomycin is subcutaneously implanted in the backs of anesthetized mice. Animals are evaluated daily for body weight change. After animals are sacrificed, collagen content and fibrosis scores are determined in skin.

Model Systems
  • C57Bl/6 Mice
Standard Readouts
  • Percent weight change
  • Terminal histopathology and/or IHC analyses
  • Skin collagen content
Additional Readouts
  • Skin immunophenotyping
  • Custom assays
Representative DataClick Image to Enlarge
Skin Histology in SC Osmotic Pump Bleomycin-Induced Dermal Fibrosis

C57Bl/6 mice are administered Bleomycin for 28 days through a SC implanted osmotic pump and Day 28 skin samples are processed for histopathology. H&E-stained skin from animals administered saline or 50 mg/kg, 100 mg/kg, or 150 mg/kg Bleomycin.

Skin Pathology in SC Osmotic Pump Bleomycin-Induced Dermal Fibrosis

C57Bl/6 mice are administered Bleomycin for 28 days through a SC implanted osmotic pump. Pathology assessment of Day 28 skin from SC Osmotic Pump-Bleomycin administered animals is shown. Dermal thickness is measured, and fibrosis score is determined in Masson’s Trichrome-stained tissue using a 0-5 semi-quantitative scoring scale of area staining positive for collagen. (*p<0.05; **p<0.01 compared to the saline-control).

Daniel Lichtman

Managing Partner